FUZEON has a unique mechanism of action compared to reverse transcriptase and protease inhibitors in that it works outside of the cell, blocking HIV before it enters the cell. FUZEON interferes with the entry of HIV-1 into cells by inhibiting fusion of viral and cellular membranes.

HIV-1 isolates with reduced susceptibility to FUZEON have been selected in vitro and have been recovered from clinical trial subjects treated with FUZEON in combination with other antiretroviral agents. HIV-1 clinical isolates resistant to NRTIs, NNRTIs and PIs were susceptible to FUZEON in cell culture.

To view an animated representation of the FUZEON mechanism of action, click on the image below.



Click here to read the full Prescribing Information for FUZEON.

Click here to read the Important Safety Information.